Alan Durkin, M.D., CEO, and medical director at Ocean Drive Plastic Surgery and Medspa (Vero Beach, FL), shares his thoughts on three trending fillers.
“The biggest development in the dermal filler arena in 2018 has been the release of Versa. Versa is a hyaluronic acid filler similar to Restylane-L, or Juvéderm XC Ultra Plus. However, clinical trials have shown decreased inflammation with Versa as compared to its more established competitors. Also, that specific company has heavily invested in its mobile app technology, providing a superior individual customer appreciation program. It is designed for the nasolabial folds and lower face.”
“Xeomin has made an enormous impact on the market after Christie Brinkley publicly came out in support of it. Xeomin, unlike Botox, has no preservative molecules, and it boasts a faster onset of action with the same duration of effect. In essence, it works faster and does the same thing as Botox. Patients are now seeing this and are requesting Xeomin much more commonly.”
“Evolus is a company that is developing a long-lasting neuromodulator. The product is called DWP-450 at this point, and they are looking to launch in the U.S. in late 2019. Keep an eye out for Evolus.”